| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/13/2002 | WO2002046140A1 Novel crystalline polymorphic forms of venlafaxine hydrochloride and a process for their preparation |
| 06/13/2002 | WO2002046138A2 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | WO2002046134A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | WO2002045753A2 Oral extended release formulation of gepirone |
| 06/13/2002 | WO2002045749A2 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/13/2002 | WO2002045734A1 Tahitian noni juice on cox-1 and cox-2 and tahitian noni juice as a selective cox-2 inhibitor |
| 06/13/2002 | WO2002045719A1 Remedies for hibernation-like symptom and agents inducing or relieving hibernation-like symptom |
| 06/13/2002 | WO2002045716A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | WO2002045715A1 Nootropic effect enhancer |
| 06/13/2002 | WO2002045713A2 Orally-bioavailable formulations of fentanyl and congeners thereof |
| 06/13/2002 | WO2002045712A1 Novel method and use |
| 06/13/2002 | WO2002045710A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 06/13/2002 | WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases |
| 06/13/2002 | WO2002045695A2 Hydrostatic delivery system for controlled delivery of agent |
| 06/13/2002 | WO2002045688A2 Composition for treatment of inflammatory disorders |
| 06/13/2002 | WO2002045658A2 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| 06/13/2002 | WO2002045652A2 Tyrosine kinase inhibitors |
| 06/13/2002 | WO2002045525A2 Aged companion pet diet |
| 06/13/2002 | WO2002045496A2 Transenic mice containing frp-rs4 gene disruptions |
| 06/13/2002 | WO2002028419A3 Chemokine mutants in the treatment of multiple sclerosis |
| 06/13/2002 | WO2002024701A3 Substituted azepino[4,5b)indole derivatives |
| 06/13/2002 | WO2002024700A3 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES |
| 06/13/2002 | WO2002022569A8 Method for producing chiral compounds |
| 06/13/2002 | WO2002022204A3 Transdermal electrotransport device and method for manufacturing same |
| 06/13/2002 | WO2002019967A3 Substituted hydrazine derivatives |
| 06/13/2002 | WO2002018334A3 Sodium channel modulators |
| 06/13/2002 | WO2002015891A3 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| 06/13/2002 | WO2002015662A3 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| 06/13/2002 | WO2002014357A3 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 06/13/2002 | WO2002012339A3 Sequences for integrin alpha-8 |
| 06/13/2002 | WO2002012245A3 Azabicyclic derivatives and their therapeutic use |
| 06/13/2002 | WO2002012244A3 Polymorphs of zaleplon and methods for the preparation thereof |
| 06/13/2002 | WO2002008222A3 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS |
| 06/13/2002 | WO2002008219A3 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 06/13/2002 | WO2002006286A3 IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| 06/13/2002 | WO2002004442A9 Azabicyclic compounds as inhibitors of nicotinic cholinergic receptors |
| 06/13/2002 | WO2001096878A3 Marker for neurodegerative diseases and its use in drug screening |
| 06/13/2002 | WO2001096330A3 Thrombin receptor antagonists |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 06/13/2002 | WO2001085257A3 Opioid antagonist compositions and dosage forms |
| 06/13/2002 | WO2001085145A3 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 06/13/2002 | WO2001079170A3 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
| 06/13/2002 | WO2001072309A3 Treatment of cerebrovascular disease |
| 06/13/2002 | WO2001070233A3 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
| 06/13/2002 | WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 06/13/2002 | WO2001044300A3 Brain specific binding members |
| 06/13/2002 | WO2001037819A3 Use of indirubine derivatives for making medicines |
| 06/13/2002 | WO2001035942A3 Analgesic compositions containing buprenorphine |
| 06/13/2002 | WO2001030335A3 Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| 06/13/2002 | WO2001029256A3 Cephalic pain susceptibility marker |
| 06/13/2002 | WO2001010444A3 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 06/13/2002 | US20020073428 Downloading and transfer of audio or video data from video broadcasts |
| 06/13/2002 | US20020072735 Multi-step drug dosage forms |
| 06/13/2002 | US20020072734 Chip systems for the controlled emission of substances having a chemosensory effect |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072616 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 06/13/2002 | US20020072611 Antipsychotic heterocycle compounds |
| 06/13/2002 | US20020072609 Process for preparing arylacetylaminothiazoles |
| 06/13/2002 | US20020072588 Recombinant antibody fragments as autoantibody antagonists |
| 06/13/2002 | US20020072539 For therapy of tumor necrosis factor(TNF), edema, neurological deficits, stroke and for therapy of pathological conditions caused by TNF-alpha |
| 06/13/2002 | US20020072538 NMDA NR2B antagonists for treatment |
| 06/13/2002 | US20020072529 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma |
| 06/13/2002 | US20020072527 Polymorphs of zaleplon and methods for the preparation thereof |
| 06/13/2002 | US20020072525 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072524 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072521 For therapy of central nervous system disorders such as stress, anxiety, depression, cardiovascular disorders, and eating disorders |
| 06/13/2002 | US20020072519 Useful as psychotherapeutic agents |
| 06/13/2002 | US20020072512 Method of preventing and treating HIV-mediated central nervous system damage |
| 06/13/2002 | US20020072509 Methods for the treatment of a traumatic central nervous system injury |
| 06/13/2002 | US20020072508 For alleviating symptoms associated with depression and mental and emotional stress |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020072101 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 06/13/2002 | US20020072083 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| 06/13/2002 | US20020071874 Compositions containing therapeutically active components having enhanced solubility |
| 06/13/2002 | US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer. |
| 06/13/2002 | DE10061057A1 Chip-Systeme zur kontrollierten Emission chemosensorisch wirkender Stoffe Chip systems for the controlled emission chemosensory of active substances |
| 06/13/2002 | DE10060145C1 Chinolin-Derivate, ihre Verwendung und diese enthaltende pharmazeutische Zusammensetzung Quinoline derivatives, their use and pharmaceutical composition containing them |
| 06/13/2002 | DE10059864A1 Substituierte Amino-furan-2-yl-essigsäure- und Amino-thien-2-yl-essigsäure-Derivate Substituted amino-furan-2-yl-acetic acid and amino-thien-2-yl-acetic acid derivatives |
| 06/13/2002 | DE10059411A1 Verwendung von 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for the therapy of urinary incontinence |
| 06/13/2002 | CA2678490A1 Isolated placental perfusate and placental cells isolated therefrom |
| 06/13/2002 | CA2437048A1 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2436916A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | CA2436899A1 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | CA2436870A1 Substituted anthranilic acids |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436692A1 Oral extended release formulation of gepirone |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2436311A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 06/13/2002 | CA2435467A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | CA2431861A1 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 06/13/2002 | CA2431374A1 Novel fibroblast growth factors |
| 06/13/2002 | CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | CA2431181A1 Nootropic effect enhancer |
| 06/13/2002 | CA2431166A1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |